Many studies have reported that CDKN2A deletion is associated with significantly shorter PFS and OS in both lower-grade glioma (LGG) and HGG (see Table 1) [48,65,86,87,88,89,90,91,92]. The gene discussed is CDKN2A; the disease is central nervous system cancer.